Company intelligence / Profile preview

Orsenix

Ownership: Private
Development stage: Phase 2

Overview

Oral arsenic trioxide capsule ORH‑2014 achieved required target exposure at 15 mg once daily in a completed Phase 1 study. The product demonstrated bioavailability and pharmacokinetic exposures similar to IV ATO and was generally well-tolerated. It received orphan drug designation from both FDA and EMA. Plans were made for a single registrational study for accelerated approval in newly diagnosed APL patients before the asset was acquired by Syros Pharmaceuticals

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

ORH-0952

Phase 2

Indications: Acute myeloid leukemia

Beyond the preview

Go deeper on Orsenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orsenix.

Explore the full profile